IFPMA’s 10 principles on counterfeit medicines
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) published its “Ten Principles on Counterfeit Medicines” to draw public attention to the issue.
Read more
Fake medicines put patients and the general public at risk. Patients believe they are receiving genuine treatment, but instead they are getting potentially dangerous products that could increase resistance to real treatments, and cause further illness, disability or even death. Fight the Fakes campaign (www.fightthefakes.org) will raise awareness about the dangers of fake medicines by...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) published its “Ten Principles on Counterfeit Medicines” to draw public attention to the issue.
Read more
The recent United Nations Summit on MDGs fueled the final push to achieve health-related Millennium Development Goals and focused attention on new Sustainable Development Goals (SDGs). It also caused me to revisit a 2011 report on improving access to drugs non-communicable diseases (NCDs) in developing countries and a report that I contributed to a John...
Read moreEvery day, fake medicines find their way into online and physical pharmacies, hospitals, and street markets. This plague knows no borders. In the best case scenario, fake medicines leave patients with no side-effects but also without a cure. In many other cases, however, they can kill people. We have to get smarter than the criminals...
Read moreInternational Regulatory Workshop Biotherapeutic Meidicines Regulatory Challenges and current practices. Approaches for harmonization.
Read moreInternational Regulatory Workshop Biotherapeutic Medicines Regulatory Challenges and current practices. Approaches for harmonization.
Read moreInternational Regulatory Workshop Biotherapeutic Meidicines Regulatory Challenges and current practices. Approaches for harmonization. Day 2. Session 1 Immunological safety, pharmacovigiliance and risk minimization programs for the biological products.
Read moreInternational Regulatory Workshop Biotherapeutic Meidicines Regulatory Challenges and current practices. Approaches for harmonization. Day 1 – Session 1 Approaches to regulation of biotherapeutic medicines. Global and regional perspective
Read moreIFPMA Statement at mhGAP Forum, Geneva, October 7, 2013 Delivered by Mario Ottiglio, Director, Global Health Policy & Public Affairs Thank you for the opportunity to contribute to this leading discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations worldwide. IFPMA highly commends the WHO Secretariat for its...
Read moreLast May the WHO launched its Global Action Plan on Mental Health. This plan captures years of hard work and offers a clear road map to tackle a global health priority. Mental and neurological disorders—MNDs—go too often silent and yet exert a paramount toll on individuals, societies, and the economy. The plan also gives the...
Read moreThis video illustrates the value of innovation — both revolutionary and incremental — in the biopharmaceutical field. With a specific focus on incremental innovation, it explains how the continuous investments in R&D, and consequent advances in available treatments, have bettered the lives of millions patients all around the world.
Read more